Drug details

Nyvepria (pegfilgrastim-apgf injection)

type of Hematopoietic Growth Factors

Nyvepria (pegfilgrastim-apgf) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Nyvepria is biosimilar to Neulasta (pegfilgrastim).

This drug may have the following side effects:

• pain in extremities
• bone pain and

The following drugs are related to Nyvepria, either as a replacement or used together:

• Soliris (eculizumab)
• Neulasta (pegfilgrastim)
• Ziextenzo (pegfilgrastim-bmez injection)
• Udenyca (pegfilgrastim-cbqv injection)
• Stimufend (pegfilgrastim-fpgk)
• Rituxan (rituximab)
• Rituxan Hycela (rituximab and hyaluronidase human injection)
• Yondelis (trabectedin for injection)